[Prognosis criteria of optical coherence tomography angiography for the long-term efficacy of anti-VEGF therapy of neovascular age-related macular degeneration].

Purpose: The study aimed to determine the most significant optical coherence tomography angiography (OCTA) parameters in terms of predicting anti-VEGF therapy effectiveness during long-term (3-year) follow-up of patients with neovascular age-related macular degeneration (nAMD).

Material And Methods: The study included 122 patients (122 eyes) with mean age of 73.4±6.

[Three-year follow-up study of clinical effectiveness of antiangiogenic therapy for neovascular age-related macular degeneration].

Purpose: The study analyzes long-term (three years) clinical effectiveness of anti-VEGF treatment of neovascular age-related macular degeneration (nAMD) and attempts to identify the most clinically significant associations between the functional and structural parameters.

Material And Methods: The study included 122 patients (122 eyes) diagnosed with nAMD, mean age -73.4±6.

[New findings on pathogenetic mechanisms in the development of age-related macular degeneration].

Age-related macular degeneration (AMD) is a complex multifactorial disease that occurs due to disfunction and degeneration of retinal pigment epithelium (RPE) and choriocapillaris, as well as death of photoreceptors. The exact pathogenetic mechanism remains uncertain. The aging process is the main and the clearest risk factor of AMD.

[Anti-VEGF therapy for age-related macular degeneration].

Purpose: To evaluate the clinical effectiveness of aflibercept in treatment of patients with neovascular age-related macular degeneration (nAMD).

Material And Methods: The first group included 156 treatment-naive nAMD patients (156 eyes). The second group consisted of 29 patients (38 eyes) with nAMD who had previously received at least 3 loading injections of 0.

[Anti-VEGF therapy for diabetic macular edema. From theory to clinical practice].

Purpose: To evaluate clinical effectiveness of aflibercept therapy for patients with diabetic macular edema (DME) - both naïve to the drug and unresponsive to previous anti-VEGF treatment.

Material And Methods: The study included 127 patients (127 eyes) divided into two groups. The first group consisted of 100 primary DME patients (100 eyes) with mean age of 68.